Abstract
Thirty-five patients with advanced-stage metastatic or unresectable gastric adenocarcinoma were given combination chemotherapy consisting of fluorouracil, doxorubicin, and 1,3-bis (2-chlorbethyl)-1-nitrosourea. Two patients achieved complete remission and 16 partial remission to give an overall response rate of 52%. Six further patients (17%) had stable disease, while in 11 (31%) the disease showed clear-cut progression despite treatment. The only pretreatment factors that suggested poor prognosis were poor initial patient performance and the stomach as the predominant site of disease. Patients responding to treatment had a significantly longer time to relapse (median 48 weeks) than patients with stable disease (median 16 weeks) and a significantly improved survival time (medians, 52 weeks with 30% of patients' living at 88 weeks and 32 weeks with all dead at 64 weeks respectively). Comparing these results with those in other reports indicated that the three-drug combination chemotherapy consisting of fluorouracil, doxorubicin, and either a nitrosourea or mitomycin was superior to single and two-drug regimens and currently represents the optimum treatment for advanced-stage gastric cancer. Gastric adenocarcinoma should now be considered to be a gastrointestinal malignancy that is relatively susceptible to chemotherapy, and studies of these improved chemotherapeutic regimens as post-surgical adjuvants may lead to further improvements in prognosis.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Baker L. H., Vaitkevicius V. K., Gehan E. Randomized prospective trial comparing 5-fluorouracil (NSC-19893) to 5-fluorouracil and methyl-CCNU (NSC-95441) in advanced gastrointestinal cancer. Cancer Treat Rep. 1976 Jun;60(6):733–737. [PubMed] [Google Scholar]
- Carter S. K., Comis R. L. Gastric cancer: current status of treatment. J Natl Cancer Inst. 1977 Mar;58(3):567–578. doi: 10.1093/jnci/58.3.567. [DOI] [PubMed] [Google Scholar]
- Douglass H. O., Jr, Lavin P. T., Moertel C. G. Nitrosoureas: useful agents for the treatment of advanced gastrointestinal cancer. Cancer Treat Rep. 1976 Jun;60(6):769–780. [PubMed] [Google Scholar]
- Moertel C. G., Childs D. S., Jr, Reitemeier R. J., Colby M. Y., Jr, Holbrook M. A. Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet. 1969 Oct 25;2(7626):865–867. doi: 10.1016/s0140-6736(69)92326-5. [DOI] [PubMed] [Google Scholar]
- Moertel C. G., Mittelman J. A., Bakemeier R. F., Engstrom P., Hanley J. Sequential and combination chemotherapy of advanced gastric cancer. Cancer. 1976 Aug;38(2):678–682. doi: 10.1002/1097-0142(197608)38:2<678::aid-cncr2820380209>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
- Moertel C. G., Reitemeier R. J., Hahn R. G. Mitomycin C therapy in advanced gastrointestinal cancer. JAMA. 1968 Jun 17;204(12):1045–1048. [PubMed] [Google Scholar]
- Moertel C. G. The natural history of advanced gastric cancer. Surg Gynecol Obstet. 1968 May;126(5):1071–1074. [PubMed] [Google Scholar]
- Reitemeier R. J., Moertel C. G., Hahn R. G. Combination chemotherapy in gastrointestinal cancer. Cancer Res. 1970 May;30(5):1425–1428. [PubMed] [Google Scholar]
- Schein P. S., Macdonald J. S., Hoth D., Wooley P. V. Mitomycin C: experience in the United States, with emphasis on gastric cancer. Cancer Chemother Pharmacol. 1978;1(2):73–75. doi: 10.1007/BF00254039. [DOI] [PubMed] [Google Scholar]